TENAX THERAPEUTICS, INC. financial data

Symbol
TENX on Nasdaq
Location
Chapel Hill, NC
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2517% % 83%
Debt-to-equity 4% % -47%
Return On Equity -43% % 26%
Return On Assets -42% % 23%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,243,575 shares 83%
Common Stock, Shares, Outstanding 5,907,233 shares 73%
Common Stock, Value, Issued $1,000 USD 193%
Weighted Average Number of Shares Outstanding, Basic 39,741,404 shares 88%
Weighted Average Number of Shares Outstanding, Diluted 39,741,404 shares 88%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $26,726,000 USD 172%
General and Administrative Expense $20,505,000 USD 258%
Operating Income (Loss) $47,231,000 USD -112%
Net Income (Loss) Attributable to Parent $43,326,000 USD -134%
Earnings Per Share, Basic 3 USD/shares -111%
Earnings Per Share, Diluted 3 USD/shares -111%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $99,400,000 USD
Other Assets, Current $88,000 USD 32%
Assets, Current $102,810,000 USD 3%
Other Assets, Noncurrent $0 USD -100%
Assets $102,810,000 USD 3%
Accounts Payable, Current $5,608,000 USD 254%
Employee-related Liabilities, Current $858,000 USD -1.6%
Accrued Liabilities, Current $991,000 USD 1.4%
Liabilities, Current $6,599,000 USD 158%
Liabilities $6,599,000 USD 158%
Retained Earnings (Accumulated Deficit) $351,914,000 USD -14%
Stockholders' Equity Attributable to Parent $96,211,000 USD -1%
Liabilities and Equity $102,810,000 USD 3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,967,000 USD -35%
Net Cash Provided by (Used in) Financing Activities $23,563,000 USD 197%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 5,907,233 shares 73%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $99,369,000 USD 1.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $41,701,000 USD 7.8%
Deferred Tax Assets, Operating Loss Carryforwards $37,639,000 USD 2.2%
Additional Paid in Capital $448,124,000 USD 10%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $14,963,000 USD 61011%
Interest Expense $23,000 USD -4.2%